FitLife Brands Announces Second Quarter 2024 Results

Source: GlobeNewswire
FitLife Brands Announces Second Quarter 2024 Results

Omaha, Aug. 14, 2024 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. (“FitLife” or the “Company”) (NASDAQ: FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the second quarter ended June 30, 2024.

Highlights for the second quarter ended June 30, 2024 include:

  • Total revenue was $16.9 million, an increase of 15% compared to the second quarter of 2023.  
  • Online sales were $11.2 million, representing 66% of total revenue and an increase of 13% compared to the second quarter of 2023.
  • Gross margin was 44.8% compared to 40.4% during the second quarter of 2023.
  • Net income was $2.6 million compared to $2.0 million during the second quarter of 2023.
  • Basic earnings per share and diluted earnings per share were $0.57 and $0.53, respectively, compared to $0.44 and $0.40 during the second quarter of 2023.
  • Adjusted EBITDA was $3.8 million, a 29% increase compared to the second quarter of 2023.
  • The Company ended the quarter with $15.4 million outstanding on its term loans and cash of $3.7 million, or total net debt of $11.7 million.

For the second quarter ended June 30, 2024, total revenue was $16.9 million, an increase of 15% compared to $14.8 million during the same period last year. Online revenue for the quarter was $11.2 million, an increase of 13% compared to the quarter ended June 30, 2023. Online revenue accounted for 66% and 67% of the Company’s total revenue during the quarters ended June 30, 2024 and 2023, respectively.

Wholesale revenue for the quarter ended June 30, 2024 was $5.7 million, an increase of 18% compared to the same period last year.   The Company’s recent acquisitions of Mimi’s Rock Corp (“MRC”) and the MusclePharm assets contributed $1.5 million of wholesale revenue during the second quarter of 2024, while Legacy FitLife wholesale revenue was down $0.5 million, or 10%, compared to the same period last year.  

Gross margin for the quarter ended June 30, 2024 was 44.8% compared to 40.4% during the same period in the prior year. Excluding the impact of the inventory step-up resulting from the acquisition of MRC, gross margin during the quarter ended June 30, 2023 would have been 41.9%.

Net income for the second quarter of 2024 was $2.6 million compared to $2.0 million during the quarter ended June 30, 2023. Basic and diluted earnings per share were $0.57 and $0.53 respectively, compared to $0.44 and $0.40 during the second quarter of 2023.   Net income during the second quarter of 2023 was adversely impacted by $0.1 million of merger and acquisition related costs as well as $0.2 from the amortization of the inventory step-up from the MRC acquisition.

Adjusted EBITDA for the quarter ended June 30, 2024 was $3.8 million, an increase of 29% compared to the same period in 2023. Adjusted EBITDA for the last twelve months, which includes four full quarters of MRC’s financial performance but approximately only two and a half quarters of MusclePharm, was $12.4 million.

As of June 30, 2024, the Company had $15.4 million outstanding on its term loans and cash of $3.7 million, or total net debt of approximately $11.7 million. The Company’s $3.5 million revolving line of credit remains undrawn.

Performance of Acquired Brands

Management frequently receives questions from investors regarding the performance of brands subsequent to their acquisition by the Company. In an effort to be responsive to these questions, the Company has provided additional disclosure in this press release and in the Management’s Discussion and Analysis section of the Company’s Form 10-Q filed with the SEC. The Company currently intends to provide this level of disclosure for no more than two years following a transaction, after which the performance of acquired brands will be reported as part of Legacy FitLife results.

One of the primary metrics used by management to evaluate the performance of the Company’s brands is contribution, a non-GAAP financial measure which management defines as gross profit less advertising and marketing expenditures.   Other companies may also report contribution as a performance metric, but their definition or calculation of contribution may differ from the Company’s. Management believes that contribution, as defined by the Company, is a particularly relevant performance metric since it incorporates the gross profit associated with a specific brand or collection of brands as well as the advertising and marketing expenditures associated with the same brand or brands. With limited exceptions, other operating expenses incurred by the Company are generally not allocable to a specific brand or collection of brands.

Other than for MusclePharm, the numbers in the contribution tables presented below in the body of the press release represent the performance of a collection of brands. Legacy FitLife consists of nine brands and MRC consists of three brands. These collections of brands do not meet the definition of operating segments and are not managed as such.

Legacy FitLife      
(Unaudited)      
 20232024 
 Q2Q3Q4 Q1Q2
 Wholesale revenue4,715 4,361 4,011  4,506 4,224 
 Online revenue2,418 2,339 2,134  2,455 2,578 
 Total revenue7,133 6,700 6,145  6,961 6,802 
 Gross profit2,999 2,490 2,480  2,928 3,006 
Gross margin42.0%37.2%40.4% 42.1%44.2%
Advertising and marketing63 79 71  80 94 
Contribution2,936 2,411 2,409  2,848 2,912 
Contribution as a % of revenue41.2%36.0%39.2% 40.9%42.8%


For the second quarter of 2024, legacy FitLife revenue declined 5% compared to the same period last year, driven by a 10% decline in wholesale revenue partially offset by 7% increase in online revenue.

Despite the revenue decline, gross profit for legacy FitLife increased slightly and contribution decreased slightly compared to the same period last year. Gross margin increased from 42.0% during the second quarter of 2023 to 44.2% during the second quarter of 2024. Contribution as a percentage of revenue increased from 41.2% to 42.8% over the same time period.

The Company’s wholesale revenue continues to be challenged by declining customer counts in the brick-and-mortar stores of our wholesale partners. However, at least some of the customers choosing to no longer shop in brick-and-mortar locations continue to purchase legacy FitLife products online, and when a customer buys online the Company earns substantially higher gross profit and contribution. More specifically, on a year-over-year basis during the second quarter of 2024, wholesale revenue for legacy FitLife declined by $0.5 million and online revenue increased by $0.2 million, yet gross profit and contribution were approximately unchanged compared to the same period last year.

        
Mimi's Rock (MRC)       
(Unaudited)       
 20232024  
 Q2Q3Q4 Q1Q2 
 Wholesale revenue137 85 91  94 90  
 Online revenue7,490 7,117 6,811  7,399 7,371  
 Total revenue7,627 7,202 6,902  7,493 7,461  
 Gross profit2,966 3,206 2,790  3,520 3,597  
Gross margin38.9%44.5%40.4% 47.0%48.2% 
Advertising and marketing1,394 1,196 846  1,062 1,071  
Contribution1,572 2,010 1,944  2,458 2,526  
Contribution as % of revenue20.6%27.9%28.2% 32.8%33.9% 
        

For the second quarter of 2024, MRC revenue declined 2% compared to the same period in 2023. Over the same time period, gross profit increased 21% and contribution increased 61%.  

For the second quarter of 2024, gross margin increased to 48.2% from 38.9% last year. Excluding the impact of the inventory step-up resulting from the acquisition of MRC, gross margin during the quarter ended June 30, 2023 would have been 41.7%.

Revenue for the largest MRC brand—Dr. Tobias—increased 4% while revenue for the skin care brands—Maritime Naturals and All Natural Advice—declined 37% in the second quarter of 2024.

At the time of the MRC acquisition in 2023, the skin care brands were sold in a number of countries. Analysis subsequent to the acquisition determined that—in almost all countries other than Canada and the US—the products were being sold at levels resulting in negative contribution. Even worse, in many of those countries, the products were being sold at negative gross margins.

To optimize performance of the skin care brands, management exited a number of countries and raised prices in other countries. As a result of these changes, a substantial amount of unprofitable revenue was eliminated.

The substantial year-over-year increase in gross profit for the MRC brands is primarily the result of this optimization of the skin care brands as well as beneficial product mix within the Dr. Tobias brand. The substantial year-over-year increase in contribution for the MRC brands is a function of the optimization of the skin care brands, beneficial product mix within the Dr. Tobias brand, as well as the optimization of advertising spend across all MRC brands.

MusclePharm       
(Unaudited)       
 20232024  
 Q2Q3Q4 Q1Q2 
 Wholesale revenue- - 180  1,117 1,388  
 Online revenue- - 73  978 1,279  
 Total revenue- - 253  2,095 2,667  
 Gross profit- - 93  839 977  
Gross margin0.0%0.0%36.8% 40.0%36.6% 
Advertising and marketing- - -  86 161  
Contribution- - 93  753 816  
Contribution as % of revenue0.0%0.0%36.8% 35.9%30.6% 
        

MusclePharm revenue increased 27% sequentially from the first quarter of 2024 to the second quarter of 2024, with wholesale revenue increasing 24% and online revenue increasing 31%.

In an effort to drive revenue growth, the Company is making targeted investments in advertising and promotion in both the wholesale and online channels.   As a result of these investments, gross margin and contribution as a percentage of revenue declined, although total gross profit and contribution in dollar terms increased sequentially.

In addition, the Company is exploring additional new product launches and continues to have productive discussions with a number of potential new wholesale partners.

FitLife Consolidated       
(Unaudited)       
 20232024  
 Q2Q3Q4 Q1Q2 
        
 Wholesale revenue4,852 4,446 4,282  5,717 5,702  
 Online revenue9,908 9,456 9,018  10,832 11,228  
 Total revenue14,760 13,902 13,300  16,549 16,930  
 Gross profit5,965 5,696 5,363  7,287 7,580  
Gross margin40.4%41.0%40.3% 44.0%44.8% 
Advertising and marketing1,457 1,275 917  1,228 1,326  
Contribution4,508 4,421 4,446  6,059 6,254  
Contribution as % of revenue30.5%31.8%33.4% 36.6%36.9% 
        

For the Company overall, revenue increased 15%, gross profit increased 27%, and contribution increased 39% compared to the second quarter of 2023.

Gross margin increased to 44.8% compared to 40.4% during the second quarter of last year, or 41.9% excluding the impact of the inventory step-up resulting from the acquisition of MRC.

Contribution as a percentage of revenue increased to 36.9% compared to 30.5% during the second quarter of last year, or 32.0% excluding the impact of the inventory step-up resulting from the acquisition of MRC.

Management Commentary

Dayton Judd, the Company’s Chairman and CEO commented, “During the second quarter of 2024, the Company continued to see many bright spots in our business. At MRC, the Dr. Tobias brand—which represents approximately 90% of the MRC business—continued to grow despite significant year-over-year reductions in advertising and marketing spend. And although revenue for MRC’s skin care brands has declined significantly due to our decision to exit unprofitable markets and raise prices in others, the brands are substantially more profitable. The MRC brands’ collective contribution of approximately $8.9 million over the last twelve months compares very favorably to the $17.1 million acquisition price the Company paid for MRC.

“Although our legacy FitLife brands continue to face headwinds in the wholesale channel due to declining foot traffic at our brick-and-mortar retail partners, the transition of even a small portion of that lost wholesale revenue to the online channel means the Company’s profitability is not diminished. Online revenue growth for the legacy FitLife brands thus far during the third quarter continues to be encouraging.

“With regard to MusclePharm, we are encouraged by the sequential growth the brand has experienced under our ownership and we intend to invest in advertising and promotion to drive continued growth.

“Overall, I am pleased with the strong performance of our brands, which would not be possible without the continued dedication of each FitLife team member. The Company’s balance sheet is strong, with net debt now representing approximately only 0.9x adjusted EBITDA. Although no transaction is imminent, the Company is currently electing to build cash as it continues to evaluate M&A opportunities. As of August 13, 2024, the Company’s cash balance was $4.4 million.”

Earnings Conference Call

The Company will hold an investor conference call on Wednesday, August 14, 2024 at 4:30 pm ET. Investors interested in participating in the live call can dial (833) 492-0064 from the U.S. and provide the conference identification code of 266347. International participants can dial (973) 528-0163 and provide the same code.

About FitLife Brands
FitLife Brands is a developer and marketer of innovative and proprietary nutritional supplements and wellness products for health-conscious consumers. FitLife markets more than 250 different products primarily online, but also through domestic and international GNC® franchise locations as well as through approximately 16,000 additional domestic retail locations. FitLife is headquartered in Omaha, Nebraska. For more information, please visit our website at www.fitlifebrands.com.

Forward-Looking Statements
Statements in this release that are forward looking involve known and unknown risks and uncertainties, which may cause the Company's actual results in future periods to be materially different from any future performance that may be suggested in this news release. Such factors may include, but are not limited to, the ability of the Company to continue to grow revenue, and the Company's ability to continue to achieve positive cash flow given the Company's existing and anticipated operating and other costs. Many of these risks and uncertainties are beyond the Company's control. Reference is made to the discussion of risk factors detailed in the Company's filings with the Securities and Exchange Commission including its reports on Form 10-K and 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the dates on which they are made.

FITLIFE BRANDS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except per share data)

  June 30,
2024
  December 31,
2023
 
  (Unaudited)     
ASSETS:        
CURRENT ASSETS        
Cash and cash equivalents $3,680  $1,139 
Restricted cash  55   759 
Accounts receivable, net of allowance of doubtful accounts of $18 and $17, respectively  2,498   2,046 
Inventories, net of allowance for obsolescence of $69 and $162, respectively  9,779   9,091 
Sales tax receivable  111   1,019 
Prepaid expense and other current assets  911   639 
Total current assets  17,034   14,693 
         
Property and equipment, net  106   137 
Right of use asset  73   121 
Intangibles, net of amortization of $134 and $113, respectively  26,308   26,309 
Goodwill  13,108   13,294 
Deferred tax asset  682   792 
TOTAL ASSETS $57,311  $55,346 
         
LIABILITIES AND STOCKHOLDERS' EQUITY:        
CURRENT LIABILITIES:        
Accounts payable $4,309  $3,261 
Accrued expense and other liabilities  1,082   1,026 
Income taxes payable  1,844   892 
Product returns  530   571 
Term loan – current portion  4,500   4,500 
Lease liability - current portion  58   87 
Total current liabilities  12,323   10,337 
         
Term loan, net of current portion and unamortized deferred finance costs  10,778   15,509 
Long-term lease liability, net of current portion  25   51 
Deferred tax liability  2,329   2,413 
TOTAL LIABILITIES  25,455   28,310 
         
STOCKHOLDERS’ EQUITY:        
Preferred stock, $0.01 par value, 10,000 shares authorized, none outstanding as of June 30, 2024 and December 31, 2023  -   - 
Common stock, $0.01 par value, 60,000 shares authorized; 4,598 issued and outstanding as of June 30, 2024 and December 31, 2023  46   46 
Additional paid-in capital  30,902   30,699 
Retained earnings (accumulated deficit)  1,371   (3,417)
Foreign currency translation adjustment  (463)  (292)
TOTAL STOCKHOLDERS' EQUITY  31,856   27,036 
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $57,311  $55,346 

FITLIFE BRANDS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023
(In thousands, except per share data)
(Unaudited)

  Three months ended June 30  Six months ended
June 30
 
  2024  2023  2024  2023 
                 
Revenue $16,930  $14,760  $33,479  $25,498 
Cost of goods sold  9,350   8,795   18,612   15,125 
Gross profit  7,580   5,965   14,867   10,373 
                 
OPERATING EXPENSE:                
Advertising and marketing  1,326   1,457   2,554   2,084 
Selling, general and administrative  2,528   1,786   5,036   3,502 
Merger and acquisition related  24   115   158   1,487 
Depreciation and amortization  27   23   63   42 
Total operating expense  3,905   3,381   7,811   7,115 
                 
OPERATING INCOME  3,675   2,584   7,056   3,258 
                 
OTHER EXPENSE (INCOME)                
Interest income  (17)  (66)  (22)  (150)
Interest expense  345   251   759   349 
Foreign exchange (gain) loss  (10)  (200)  (5)  (117)
Total other expense (income)  318   (15)  732   82 
                 
INCOME BEFORE INCOME TAX PROVISION  3,357   2,599   6,324   3,176 
                 
PROVISION FOR INCOME TAXES  729   635   1,536   1,056 
                 
NET INCOME $2,628  $1,964  $4,788  $2,120 
                 
NET INCOME PER SHARE                
Basic $0.57  $0.44  $1.04  $0.47 
Diluted $0.53  $0.40  $0.97  $0.43 
Basic weighted average common shares  4,598   4,446   4,598   4,464 
Diluted weighted average common shares  4,950   4,887   4,931   4,906 
                 

FITLIFE BRANDS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE SIX MONTHS ENDED JUNE 30, 2024 AND 2023
(In thousands)
(Unaudited)

  Six months ended June 30, 
  2024  2023 
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net income $4,788  $2,120 
Adjustments to reconcile net income to net cash provided by operating activities:        
Depreciation and amortization  63   42 
Allowance for doubtful accounts  1   (17)
Allowance for inventory obsolescence  (93)  15 
Stock-based compensation  203   74 
Amortization of deferred financing costs  19   5 
Changes in operating assets and liabilities:        
Accounts receivable - trade  (480)  (429)
Inventories  (641)  1,164 
Deferred tax asset  110   503 
Prepaid expense, other current assets and sales tax receivable  770   (472)
Right-of-use asset  45   38 
Accounts payable  1,064   (1,611)
Lease liability  (53)  (39)
Accrued expense, other liabilities and income taxes payable  851   401 
Product returns  (41)  - 
Net cash provided by operating activities  6,606   1,794 
         
CASH FLOWS FROM INVESTING ACTIVITIES:        
Purchase of property and equipment  (10)  (54)
Cash paid for acquisition of Mimi’s Rock Corp.  -   (17,099)
Net cash used in investing activities  (10)  (17,153)
         
CASH FLOWS FROM FINANCING ACTIVITIES:        
Payments on term loans  (4,750)  (625)
Proceeds from term loans  -   12,500 
Net cash provided by (used in) financing activities  (4,750)  11,875 
         
Foreign currency impact on cash  (9)  40 
         
CHANGE IN CASH AND RESTRICTED CASH  1,837   (3,444)
CASH AND RESTRICTED CASH, BEGINNING OF PERIOD  1,898   13,277 
CASH AND RESTRICTED CASH, END OF PERIOD $3,735  $9,833 


Supplemental cash flow disclosure        
Cash paid for income taxes $517  $241 
Cash paid for interest, net of amounts capitalized $761  $213 

Non-GAAP Financial Measures 
  
The financial information included in this release and the presentation below contain certain financial measures defined as “non-GAAP financial measures” by the SEC, including non-GAAP EBITDA and non-GAAP adjusted EBITDA. These measures may be different from non-GAAP financial measures used by other companies. The presentation of this financial information, which is not prepared under any comprehensive set of accounting rules or principles, is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. 
  
As presented below, non-GAAP EBITDA excludes interest, income taxes, depreciation and amortization and foreign currency gain/loss. Adjusted non-GAAP EBITDA excludes, in addition to interest, taxes, depreciation and amortization and foreign currency gain/loss, equity-based compensation, M&A/integration expense and non-recurring gains or losses. The Company believes the non-GAAP measures provide useful information to both management and investors by excluding certain expense and other items that may not be indicative of its core operating results and business outlook. The Company believes that the inclusion of non-GAAP measures in the financial presentation below allows investors to compare the Company’s financial results with the Company’s historical financial results and is an important measure of the Company’s comparative financial performance. 

The Company’s calculation of Adjusted EBITDA for the three and six months ended June 30, 2024 and 2023 is as follows:

  For the three months ended
June 30,
  For the six months ended
June 30,
 
  2024  2023  2024  2023 
  (Unaudited)  (Unaudited)  (Unaudited)  (Unaudited) 
Net income $2,628  $1,964  $4,788  $2,120 
Interest expense  345   251   759   349 
Interest income  (17)  (66)  (22)  (150)
Foreign exchange (gain) loss  (10)  (200)  (5)  (117)
Provision for income taxes  729   635   1,536   1,056 
Depreciation and amortization  27   23   63   42 
EBITDA  3,702   2,607   7,119   3,300 
Non-cash and non-recurring adjustments                
Stock-based compensation  101   31   203   74 
Merger and acquisition related  24   115   158   1,487 
Amortization of inventory step-up  -   213   -   323 
Non-recurring loss on foreign currency forward contract  -   -   -   112 
Adjusted EBITDA $3,827  $2,966  $7,480  $5,296